Yuichiro Ohe mainly focuses on Lung cancer, Internal medicine, Oncology, Surgery and Cancer research. His study in Lung cancer is interdisciplinary in nature, drawing from both Carcinoma, Cisplatin and Epidermal growth factor receptor. Internal medicine and Gastroenterology are commonly linked in his work.
His Oncology study integrates concerns from other disciplines, such as Prospective cohort study, Adverse effect, Pharmacology and Vandetanib. His Surgery research focuses on subjects like Hazard ratio, which are linked to Icotinib. His Cancer research research incorporates elements of Cancer cell, Transfection, Immunology, non-small cell lung cancer and PTEN.
His main research concerns Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery. His research in Internal medicine focuses on subjects like Gastroenterology, which are connected to Toxicity. The Oncology study combines topics in areas such as Nivolumab, Phases of clinical research and Docetaxel.
His Lung cancer study combines topics from a wide range of disciplines, such as Carboplatin, Cancer research, Neutropenia and Epidermal growth factor receptor. His Chemotherapy research is multidisciplinary, relying on both Regimen and Irinotecan. His Surgery study typically links adjacent topics like Hazard ratio.
His primary areas of study are Internal medicine, Oncology, Lung cancer, Nivolumab and Non small cell. His Internal medicine study frequently draws connections to other fields, such as Gastroenterology. His work deals with themes such as Cancer, Clinical trial and Chemotherapy, which intersect with Oncology.
As part of the same scientific family, Yuichiro Ohe usually focuses on Lung cancer, concentrating on Lung and intersecting with Biopsy. His work in Non small cell addresses issues such as Cancer research, which are connected to fields such as Kinase and Mutation. His research investigates the connection with Osimertinib and areas like Confidence interval which intersect with concerns in Gefitinib and Erlotinib.
His scientific interests lie mostly in Internal medicine, Lung cancer, Oncology, Nivolumab and Gastroenterology. His study in Clinical endpoint, Adverse effect, Hazard ratio, Osimertinib and Interstitial lung disease are all subfields of Internal medicine. The concepts of his Lung cancer study are interwoven with issues in Neutropenia, Clinical trial and Survival analysis.
His Neutropenia study incorporates themes from Entrectinib and Chemoradiotherapy. His work on Crizotinib as part of general Oncology research is frequently linked to Response Evaluation Criteria in Solid Tumors, bridging the gap between disciplines. His Gastroenterology research integrates issues from Progressive disease, Toxicity, Phases of clinical research, Tolerability and Nausea.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang.
The New England Journal of Medicine (2009)
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana.
The New England Journal of Medicine (2018)
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard.
The New England Journal of Medicine (2015)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho.
The New England Journal of Medicine (2020)
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
Toshimi Takano;Yuichiro Ohe;Hiromi Sakamoto;Koji Tsuta.
Journal of Clinical Oncology (2005)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Y Ohe;Y Ohashi;K Kubota;T Tamura.
Annals of Oncology (2007)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto;Katsuyuki Kiura;Makoto Nishio;Kazuhiko Nakagawa.
Lancet Oncology (2013)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Suresh S. Ramalingam;James C.-H. Yang;Chee Khoon Lee;Takayasu Kurata.
Journal of Clinical Oncology (2017)
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong.
The New England Journal of Medicine (2020)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto;Yukito Ichinose;Yuichiro Ohe;Nobuyuki Yamamoto.
Journal of Thoracic Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: